Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.

Currently viewing trials
(Last updated: May 21, 2020)

Zip Code:

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 



Hormone Therapy

Radiation Oncology


Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment



Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children


Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence





NEAREST SITE: 2260 miles
Allegheny Health Network (AHN) - Allegheny General Hospital ONLY

VISITS: 1 visit a week for 3 weeks, then monthly visits thereafter


NCT ID: NCT02738866

Palbociclib With Fulvestrant for ER+, HER2- Advanced Breast Cancer

Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor Scientific Title

To study the safety and effects (good and bad) of using Ibrance and Faslodex to treat people with advanced breast cancer who have previously been treated with Ibrance and an aromatase inhibitor.
Who is this for?
People with ER positive, HER2 negative advanced (some stage III) or metastatic (stage IV) breast cancer and have already been treated with palbociclib (Ibrance®) and an aromatase inhibitor.    Full eligibility criteria
Contact research site

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, once daily (3 weeks on, 1 week off)</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, once a week for 3 weeks then once a month thereafter</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) is a CDK4/6 inhibitor approved to treat hormone receptor positive (ER+ and/or PR+), HER2 negative breast cancer in combination with an anti-estrogen therapy. </li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is an anti-estrogen therapy approved to treat postmenopausal women with metastatic breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02738866' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://pubchem.ncbi.nlm.nih.gov/compound/Fulvestrant#section=Top' target='_blank'>PubChem: Fulvestrant</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.astrazeneca.com/media-centre/press-releases/2017/faslodex-receives-us-fda-approval-as-monotherapy-for-expanded-use-in-breast-cancer.html' target='_blank'>AstraZeneca Press Release: Fulvestrant</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancercare.org.uk/information-support/facing-breast-cancer/going-through-breast-cancer-treatment/targeted-therapy/palbociclib-ibrance#what%20is%20palbociclib' target='_blank'>BreastCancerCare UK: Palbociclib</a> </li></ul>
See more